Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

Current Research Studies

RS_GS_US_320_1092

GS_US_320_1092

Phase: II/III
Clinicaltrials.gov ID: NCT02932150

What is the goal of the study?

Randomized (2:1), double-blind, placebo-controlled, two-part, multicenter (Approximately 40 centers in North America, Europe, and Asia), study of the pharmacokinetics, safety, tolerability, and antiviral activity of the TAF 25 mg tablet administered once daily for 24 weeks in treatment-naïve and treatment-experienced adolescent subjects with CHB. A total of 75 adolescents (12 to < 18 years of age) will be enrolled to receive the TAF 25 mg tablet or matching placebo once daily.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Evelyn Hsu
Study Team Member: Teresa Chen, Teresa.Chen@seattlechildrens.org

Seattle Children’s complies with applicable federal and other civil rights laws and does not discriminate, exclude people or treat them differently based on race, color, religion (creed), sex, gender identity or expression, sexual orientation, national origin (ancestry), age, disability, or any other status protected by applicable federal, state or local law. Financial assistance for medically necessary services is based on family income and hospital resources and is provided to children under age 21 whose primary residence is in Washington, Alaska, Montana or Idaho.